TRANSFUSION—VOLUME 28 (1988)

Subject Index

In the subject index, the page number refers to the first page of the communication in which the subject is addressed rather than to the specific page on which the referenced key words can be found. An "L" in parenthesis following the page number indicates that the subject entry appeared in letters to the editor; an "E" in parenthesis indicates the subject was discussed in an editorial.

In Volume 28 (1988), Number One (January–February) contains pages 1–92; Number Two (March–April), pages 93–200; Number Three (May–June), pages 201–292; Number Four (July–August), pages 293–400; Number Five (September–October), pages 401–508; and Number Six (November–December), pages 509–614.

A

AABB standards ..... 293(E)
ABO
  antigens in platelet transfusion ..... 401(E), 456
  antigens on granulocytes 358
  removal of antibodies 556
  typing 334
Acquired immunodeficiency syndrome (AIDS)
  HIV-1 190
  HIV-2 192
Adenosine triphosphate (ATP) 34, 157, 221
Adhesives, biological 319
Admixture, bloodwarming 170
AIDS, see acquired immunodeficiency syndrome
Alanine aminotransferase (ALT) ..... 204(E), 283, 386, 392, 444
Albumin
  storage in glass containers ..... 290(L)
Alleged fathers ..... 196(L), 316
Allen phenotype 460
Alloimmunization 330, 463
ALT, see alanine aminotransferase
Aluminum contamination ..... 290(L)
Anemia
  drug induced 70
  hemolytic, associated with
    AIDS 190
    cisplatin 493
    hydrochlorothiazide 70
    thrombocytopenia 406
  hemorrhage in 406
Animal model of platelet refractoriness 103
Antibody, general
  association between red cell and HLA-antibodies 330, 463
  development after transplantation 496
  distribution among Chinese in Taiwan 350
  identification
    level of probability in ..... 85(L)
    use of hexadimethrine bromide (Polybrene) test 302
  inhibition by EDTA 177
  loss over time ..... 162, 399(L)
  optimum incubation temperature 210
  removal by immunoadsorbents 556
Antibody, specific
  anti-A 177, 456, 483
  anti-B 456
  anti-Bak^a 597
  anti-c 210, 276, 463
  anti-C 302, 463
  anti-Cr^a ..... 289(L)
  anti-D ..... 127, 162, 210, 272, 330, 339, 463, 603(L)
  anti-e 210
  anti-E 210, 272, 302, 463
  anti-En^{a}Ts 74
  anti-Fy^a 210
  anti-Fy^b 210
  anti-G 272
  anti-HLA 463
  anti-In^b 479
  anti-Jk^a 162, 210, 276, 302
  anti-Jk^b 210
  anti-Js^a 210
  anti-k 210
  anti-K 210
  anti-Kp^b 210
  anti-LKE ..... 87(L)
  anti-PI^{A1} 73, 326
  anti-PI^{A2} 597
  anti-s 210
  anti-S ..... 86(L), 210, 276
  anti-U 210
  anti-Wr^a 113
  anti-Wr^b 113
  anti-Yt^b 265
Anticoagulants
  effect on plasma factor VIII level 248, 311
Antigen, general
  AnWj, association with *Haemophilius influenze* receptor ..... 289(L)
  association with gram-negative bacteria 229
  Cromer-related 427
  distribution among Chinese in Taiwan 350
  on platelets 456
  Inab phenotype 427
  red cell, antigen strength 541
Antigen, specific
  HLA antigens
    on platelets 14
    on red cells 137
  Platelet
    Bak^a 586
    Br^a 586
    PI^{A1} 132, 326, 586
    Yuk^a 586
    Yuk^b 586
  Red cell
    A 483
    ABO ..... 401(E), 456, 483
    AnWj ..... 289(L)
    c 496
    C 342
    D ..... 330, 339, 350, 397(L)
    D$_{el}$ ..... 603(L)
    D^u 233
    e 342, 439
    Er^a ..... 87(L), 268
    Er^b 268
      inheritance of 268
      gene frequencies in 268
    Fy^a 350
    hr^B 439
    hr^S 439
    Hr^o 439
    JK3 ..... 199(L)
    K 350
    Rh17 52
    Rh29 52
    Rh33 342
    Rh46 119
    Sc1 346
    Sc2 346
    Si^a 119
    Wr^a 113
    Wr^b 113
Antiglobulin test
  crossmatch ..... 85(L), 334
  direct
    positive
      in acute leukemia ..... 398(L)
      with cisplatin 493
      with hypergammaglobulinemia 2
  hexadimethrine bromide (Polybrene) 302
  low-ionic strength 210, 302
Antithrombin III concentrate ..... 198(L)
Apheresis
  electrocardiographic findings
    in donors 371
  techniques
    interface dynamics in 588
    plasma exchange donation 307

use of
dextran in ... 42
hydroxyethyl starch in ... 257
pentastrarch in ... 257
therapeutic, use in
immune thrombocytopenic purpura ... 38
malignant paraproteinemia ... 42
Ascorbate-2-phosphate ... 157, 221
Assay, see also enzyme-linked immunoassay
automated HIV-1 antibody ... 581
azoprotein ... 24
51-Chromium release ... 322
copper sulfate screening ... 422, 467, 559
enzyme-linked antiglobulin consumption ... 519
enzyme-linked antiglobulin test ... 113
enzyme immunoassay ... 93(E), 179, 386, 412, 419
flow cytometry ... 531, 541
gelatin particle agglutination ... 581
hexadimethrine bromide antiglobulin test ... 302
HIV-1 antibody ... 184, 280, 412, 581
HTLV-1 antibody ... 93(E), 179
latex agglutination ... 291(L), 563
lymphocyte immunofluorescence ... 214
microlymhocytotoxicity ... 214
monocyte monolayer ... 398(L), 399(L)
murine monoclonal antibody immobilization of platelet antigens ... 597
papain activity ... 24
platelet enzyme-linked immunosorbent ... 214
platelet immunofluorescence ... 214, 322
platelet radioimmunoassay ... 214
radioimmunoassay ... 127, 386
rosette, using Staphylococcal protein A ... 322
titration scores ... 541
ATP, see adenosine triphosphate
Audits, transfusion ... 166
Author's instructions, detailed ... 89
information ... No.1, 22A; No.2, 200; No.3, 21A; No.4, 24A; No.6, 12A
Autologous donations
comparison with homologous ... 283, 286, 403(E)
crossovers of ... 204(E), 283, 286, 394, 403(E)
current practive ... 394
fibrinogen-based adhesive ... 319
intraoperative salvage ... 379
screening for,
alanine aminotransferase (ALT) ... 204(E)
hepatits B core antibody ... 204(E), 283
hepatitis B surface antigen ... 204(E)
HiV-1 antibody ... 204(E)

B

Babesia microti ... 59
Bacteria
association with AnWj antigen ... 289(L)
bone marrow, contamination with ... 109
Kell blood group activity ... 229
Beta$_2$ microglobulin ... 14
Biosafety practices ... 502
Blood bags, in preparation of white-cell poor components ... 261, 383
Blood components, see under specific component
Blood donors, see donors
Blood group system
Colton ... 435
Duffy ... 210
Indian ... 479
Kell ... 210, 229, 460
Kidd ... 210, 545
Lutheran ... 430
Rh ... 52, 210, 342, 439, 603(L)
Scianna ... 346
SsU ... 210
Blood grouping, automated ... 233
Blood processor, see cell separator
Blood proteins ... 8
Blood substitutes ... 375, 525
Blood transfusion complications, see transfusion reactions
Blood warming ... 170
Bone marrow
bacterial contamination in processing of ... 109
bacteriocidal properties of ... 109
Bone marrow transplantation
bacterial contamination in ... 109
peripheral blood stem cells in ... 145
Rh antibodies in ... 272
Book review ... 144, 338, 544, 548

C

Cancer, association with transfusion ... 593
Cell separators
interface dynamics ... 588
leukapheresis ... 470
peripheral blood stem cells, isolation with ... 145
platelet washing with ... 46, 291(L)
plateletpheresis ... 470
Chemotaxis, granulocyte ... 243, 362, 368
Chloroquine diphosphate elution ... 14, 132
Chromium-51 cell label
platelets ... 56, 103, 322
red cell ... 265
survival studies
platelet ... 56
red cell ... 157, 302, 479
Cisplatin ... 493
Climatic influence, on donors ... 559
CMV, see cytomegalovirus
Coagulation
hydroxyethyl starch effects on ... 257
pentastarch effects on ... 257
Coagulation factors, see individual factors
Colton, blood group system ... 435
Compatibility testing
of autologons units ... 394
immediate spin ... 85(L), 334
Complement ... 525
Component, see under specific blood product
Computerized diagnosis of transfusion reactions ... 253
Creutzfedlt-Jakob Disease ... 293(E)
Crossmatch, see compatibility testing
Cryoprecipitate
plasma exchange donation of ... 307
preparation
after cold storage ... 566
delayed ... 566
therapeutic use ... 295(E), 474
yield of factor VIII in ... 311
Cryopreservation, see individual component
Cyclosporine ... 276
Cytapheresis, see under apheresis, specific cell
Cytomegalovirus (CMV)
antibody ... 187, 563
donor antibody status ... 201(E)
prevalence in hemophiliacs ... 187
risk from fresh frozen plasma ... 604(L)
risk in neonatal transfusion recipients ... 201(E), 205
testing in stored blood ... 291(L), 563

D

DAT, see antiglobulin test
DDAVP, see 1-deamino-8-D-arginine vasopressin
1-deamino-8-D-arginine vasopressin (DDAVP)
use in factor VIII production ... 295(E), 307, 311
Delayed transfusion reactions, see transfusion reactions
Desmopressin acetate, see 1-deamno-8-D-arginine vasopressin
Detailed instructions for authors ... 89
Dextran
use in microplate D^u testing ... 233
use in plasma exchange ... 42
Dextrose ... 217
Dimethyl sulfoxide ... 151
2,3-diphosphoglycerate (2,3-DPG) ... 34, 157, 221
Direct antiglobulin test (DAT), see antiglobulin test
Donors
anemia in ... 467
apheresis, safety during ... 371
autologous
crossover of units ... 204(E), 283, 286, 403(E)
screening of
alanine aminotransferase ... 204(E), 283, 286
hepatitis B core antibody ... 204(E), 283, 286
hepatitis B surface antigen ... 204(E), 283, 286, 394
HIV-1 antibody ... 204(E), 283, 286, 394
Babesia, antibody in ... 59
comparison between autologous and homologous ... 283, 286, 403(E)

electrocardiographic findings in 371
HIV-1 follow-up and notification 280
hypogammaglobulinemia in ..... 397(L)
iron
stores in 62
supplementation of 422
parous women as 173
patient-related 142
Plasmodium falciparum in ..... 86(L)
receiving human pituitary growth hormone ..... 293(E)
safety during apheresis 371
screening
alanine aminotransferase ..... 204(E), 283, 286, 386, 392, 444
cytomegalovirus ..... 201(E), 205, 563
hemoglobin 422,467, 559
hepatitis B core antibody ..... 84(L), 204(E), 283, 286, 386, 389
hepatitis B surface antigen ..... 204(E), 283, 286
hepatitis B DNA testing ..... 84(L)
HIV-1 antibody ..... 204(E), 280, 283, 286, 298, 412, 419, 601
HIV-2 192
HTLV-1 antibody 179
STS 286
surrogate tests ..... 204(E)
Western blot 280, 412, 419
seasonal variations of deferral 559
self-exclusion 601
use of DDAVP in 311
Drug-induced cytopenia
anemia 70
thrombocytopenia 322

E

EDTA, inhibition of Anti-A_1 177
Education
efforts in
HIV-1 ..... 298, 601
physician 166
transfusion medicine 4, 536
EIA, see enzyme-linked immunoassay
Elution 14, 29, 132
Enzyme activity, standardization of 24
Enzyme-linked immunoassay (EIA)
HIV-1 antibody 412, 419
HTLV-1 antibody ..... 93(E), 179
Exclusion probability, paternity ..... 196(L), 316

F

Factor VIII
anaphylactic reaction to ..... 603(L)
effect of
citrate anticoagulants 248, 311
heat treatment 8
heparin anticoagulants 311
solvent-detergent sterilization 489
hepatitis delta transmission, risk from concentrates 18
HIV-1 transmission risk from concentrates 18, 98
plasma exchange donation 307
preparation
after cold storage 566
delayed 566
recovery from cryoprecipitate 311
Factor IX concentrate
HIV-1 transmission risk from 98
Ferritin 62
Fibronectin 8
Fibrinogen 8
Fibrinogen-based adhesive 319
Ficoll-hypaque 145
Flow cytometry 531, 541
FMLP receptors, on granulocytes 362
Fresh-frozen plasma
risk of cytomegalovirus transmission ..... 604(L)
thawing of 576
use of 4, 474, 513

G

Gammaglobulinemia
hyper 29
hypo ..... 397(L)
Glycerol 151
Glycoproteins, platelet membranes 123
Gradient
ficoll-hypaque 145
Granulocyte
ABO incompatibilities 358
adherence 237
aggregation 237
chemotaxis 243, 362, 368
effect of irradiation 368
FMLP receptors 362
leukotriene-B4 243
saline washed ..... 196(L)
storage 237, 243, 362
superoxide production 368
survival of ^{111}Indium-labeled ABO incompatible 358
transfusion reaction 173

H

HBV, see hepatitis B virus
HDN, see hemolytic disease of the newborn
HDV, see hepatitis delta virus
Health care workers, safety of 502
Hemoglobin M-Hyde Park 549
Hemoglobin S 21
Hemoglobin solution 525
Hemolysis
associated with
AIDS 190
cisplatin 493
hydrochlorothiazide 70
during storage 353
following liver transplantation 276
from blood warming 170
role of mannitol 353
Hemolytic disease of the newborn (HDN) ..... 502(L)
Hemophilia, see also individual coagulation factors
AIDS, development in 98
antibodies to cytomegalovirus in 187
antibodies to HIV-1 in 98, 187
associated with anti-En^{a}Ts 77
hepatitis delta virus in 18
HIV-1 transmission, risk of 18, 98
lymphadenopathy, development in 98
thrombocytopenia, development in 68, 98
Hepatitis B virus (HBV)
core antibody testing ..... 84(L), 204(E), 283, 286, 386, 389
DNA testing ..... 84(L)
inactivation of ..... 2(E), 8
surface antigen testing ..... 204(E), 283
Hepatitis delta virus (HDV) 18
Herpes simples virus type 1 81
HES, see hydroxyethyl starch
Hexadimenthrine bromide (Polybrene) antiglobulin test 302
Histamine 226
HIV-1, see human immunodeficiency virus type 1
HIV-2, see human immunodeficiency virus type 2
HLA
antibodies
detection of 214
development of 330
in donor-specific transfusion 137
antigens on
platelets 14
red cells 137
donor-recipient compatibility 137
types 463
typing for paternity testing 316
HTLV-1, see human T-cell lymphotropic virus type 1
HTLV-III, see human immunodeficiency virus type 1
Human immunodeficiency virus type 1 (HIV-1)
antibody ..... 204(E), 283
antibody, tests for
comparisons of 179, 581
follow-up testing and notification 280, 412
gelatin particle agglutination 581
solid phase red cell adherence immunoassay 184
Western blot 179, 280, 412
characteristics of donors 298
educational efforts 298, 601
inactivation of ..... 2(E), 8, 81, 198(L)
risk in transfusion recipients ..... 18, 87(L), 98, 419, 499
seroprevalence in donors 29

Human immunodeficiency virus type 2 (HIV-2)
global distribution ... 192
risk in transfusion recipients ... 192
seroprevalence in donors ... 192
Human pituitary growth hormone ... 293(E)
Human T-cell lymphotropic virus type 1 (HTLV-I)
antibody tests for ... 93(E)
comparisons of ... 179
Western blot ... 179
Human T-cell lymphotropic virus type III, (HTLV-III), see human immunodeficiency virus type 1
Hydroxyethyl starch (HES)
effects on coagulation ... 257
use in leukapheresis ... 257
Hypergammaglobulinemia ... 29
Hypogammaglobulinemia ... 397(L)

I

Immune globulin
immune thrombocytopenic purpura, use in ... 38
subclass determination of ... 127, 483, 519
Immune hemolysis, following liver transplantation ... 276
Immunoadsorbents ... 556
Indian, blood group system ... 479
Indium labeling
granulocytes ... 358
lymphocytes ... 151
platelets ... 46
Information for Authors ... No.1, 22A; No.2, 200; No.3, 21A; No.4, 24A; No.6, 12A
Instructions for authors, detailed ... 89
Intraoperative autologous transfusion ... 379
Iron stores in donors ... 62
Irradiation
effect
on granulocytes ... 368
on platelets ... 446, 451
Ixodes dammini ... 59

K

Kell
association with gram-negative bacteria ... 229
blood group system ... 210, 229, 460
Kidd, blood group system ... 545
Kleihauer-Bethke stain ... 506(L)

L

LAK, see lymphokine-activated killer cells
Leukapheresis ... 470
Leukotriene-B^4 ... 243
Levine, Philip ... 97
Linkage analysis ... 435
Liver transplantation, blood use in ... 474
Low-ionic-strength antiglobulin test ... 210, 302
Lutheran, blood group system ... 430
Lymphadenopathy-associated virus, see human immunodeficiency virus type 1
Lymphadenopathy, association with HIV seropositivity ... 98
Lymphocytes, cryopreservation ... 151
Lymphokine-activated killer cells (LAK) ... 531

M

Macroglobulinemia ... 302
Malaria ... 86(L)
Malignant paraproteinemia ... 42
Medical expert systems ... 253
Membrane
platelet ... 14, 123
red cell ... 77
Mannitol ... 353
Microplate testing of D^u ... 233
Microwave oven, thawing of fresh-frozen plasma ... 576
MNSs system ... 113, 119
Monoclonal antibodies ... 52, 127, 531, 597
Monocyte monolayer assay
correlation with 51-Cr red cell survival ... 265, 289(L), 399(L)
detection of anti-D ... 603(L)
effect of fresh normal serum ... 398(L)
Mononuclear cells
isolation using cell separators ... 145

N

Natural killer cells ... 531
Neonatal transfusions
granulocytes ... 173, 196(L)
risk of CMV infections ... 201(E), 205

D

Oxalate ... 157, 221

P

Papain ... 24
Parentage testing, limitations of ... 196(L), 316
Pentastarch
effects on coagulation ... 257
use in leukapheresis ... 257
Phenotyping, red cell ... 21
Plasma exchange
donation of cryoprecipitate ... 307
use of Dextran in ... 42
Platelet
aggregation response
after different modes of preparation ... 571
after filtering for leukocyte depletion ... 383
during storage ... 217
antibodies
detection using rosette assay ... 322
drug-induced ... 322
elution of ... 75, 132
specific
Bak^a ... 597
$P1^{A2}$ ... 597
antigens
ABO ... 401(E), 456
general ... 14
in Mapuches ... 586
associated IgG
beta thromboglobulin, elution of ... 14
concentrates
histamine in ... 226
leukocyte depleted ... 261, 383, 571, 604(L)
preparation of ... 470, 571
storage and preservation
agitation effect ... 123
following irradiation ... 446, 451
in artificial medium
metabolism during ... 217
pH during ... 217
protein changes during ... 123
survival
in prostaglandin E_1 ... 56
following washing ... 46
washing ... 46, 291(L)
white cells
and histamine levels in ... 226
contamination in ... 571
crossmatching techniques ... 214
IgA levels in ... 291(L)
interaction with vascular subendothelium ... 406
irradiation of ... 103, 446, 451
refractoriness ... 38, 95(E), 103, 597
survival ... 14, 56, 66, 103, 401(E), 456
transfusion, counts following ... 66
use ... 474, 513
Platletpheresis ... 470
Polyagglutination of red cells ... 85(L), 549
Polybrene, see hexadimethrine bromide
Pretransfusion testing ... 162
Probability
in antibody identification ... 85(L)
in paternity testing calculations ... 196(L), 316
Prostaglandin E_1 ... 56
Prozone phenomenon ... 334
Purpura, posttransfusion ... 73, 326

R

Radioimmunoassay, measurement of IgG subclasses ... 127
Radioimmunoprecipitation assays, HTLV-I antibody ... 179
Reagents
affect on antibody by EDTA in ... 177
automated blood grouping ... 233

interference with ionic strength ..... 198(L)
non-cellular immunoadsorbents 556
papain 24
Red cell
antigen strength 541, 545
donor-specific transfusions 137
genes
Co 435
Dc(e) 439
In(Lu) 430
Jk 545
leukocyte depleted ..... 261, 506(L), 507(L)
membranes 99, 549
osmotic lysis 21, 170
phenotyping 21
preservation
role of
2,3-DPG 157, 221
mannitol 353
oxalate 157, 221
xanthone additives 34
storage temperature 221
survival ..... 157, 265, 289(L)
use 474, 513
warming 170
washing 21
Rh, blood group system ..... 52, 429, 603(L)
Rh immune globulin preparation of 127

S

Safety, of health care workers 502
Saline solutions, in blood warming 170
Serological test for syphillis (STS) 286
Sialoglycoprotein, red cell 77, 113, 119, 549
Sickle cell anemia, red cell phenotyping in 21
Stem cells 145
isolation of 145
peripheral blood 145
Storage, see individual component
STS, see serological test for syphillis
Supercritical fluid fractionation 375
Surfactants 375
Surrogate tests ..... 204(E)

T

Test kits, see assay
Thrombocytopenia
associated with
anemia 406
HIV-1 antibody 98
drug-induced 322
immune 38, 68, 73
Transfusion, see also individual components
fresh-frozen plasma 4,474,513,604
granulocytes ..... 173, 196(L)
platelets 66, 474, 513
red cells 474, 513
Transfusion, audits 166
Transfusion medicine
education in 4, 536
general ..... 1(E), 297(E), 509(E), 511(E)
Transfusion practice
assessment of 166
component therapy ..... 4, 474, 511(E), 513, 536
cost analysis 379
individual components
granulocyte 173
red cell
association with cancer 593
donor specific 137
intraoperative salvage 379
liver transplantation 474
Transfusion reaction
anaphylactic ..... 603(L)
computerized consultation program 253
delayed 162, 276, 479
due to granulocytes 173
hemolytic 77, 302, 483
histamine-associated 226
pulmonary 173
Transfusion transmitted diseases
babesiosis 59
cytomegalovirus ..... 201(E), 205, 604(L)
hepatitis delta virus 18
HIV-1 transmission risk ..... 18, 87(L), 98, 419, 499
HIV-2 transmission risk 192
HTLV-I transmission risk ..... 93(E)
Malaria ..... 86(L)
Transplacental hemorrhage ..... 506(L)
Transplantation
bone marrow
red cell antibodies following 272
liver
blood use in 474
delayed immune hemolysis in 276
renal 137, 496
risk of human immunodeficiency virus
transmission ..... 87(L)
Typing reagents
ABO 334
anti-D, chemically modified 339

U

Utilization, blood 4, 166
Ultraviolet radiation ..... 2(E)
Urea-dependent lysis test ..... 197(L), 545

V

Viral inactivation
heat treatment 8
pasteurization ..... 198(L)
solvent-detergent 489
ultraviolet light ..... 2(E), 81
von Willebrand's disease 489
von Willebrand's factor 8

W

Western blot
comparison of assays 280
evaluation and follow-up of atypical reactivity 280, 412
HTLV-I 179
Whole blood 4

X

Xanthone additives 34